-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们将LCID的12个月目标价从10美元下调至6美元。鉴于LCID第一季度财报表现弱于预期，我们维持对LCID股票的“持有”评级。我们将2026年调整后每股收益预期从-12.70美元下调至-12.00美元，并将2027年调整后每股收益预期从-11.45美元下调至-11.10美元。LCID第一季度调整后每股收益为-2.82美元，低于市场预期的-2.04美元，远低于市场普遍预期的-2.30美元。受价格上涨的推动，LCID第一季度营收增长20%至2.825亿美元（比市场普遍预期低7600万美元），但汽车总销量下降1%至3093辆。在本次公告中，LCID并未更新此前发布的2026年2.5万至2.7万辆的产量预期（该预期较2025年的1.784万辆有所增长）。我们认为，LCID加速消耗现金和不断攀升的库存表明其仍面临持续风险。该公司在竞争激烈的豪华电动汽车市场中寻求站稳脚跟，其能否在满足巨额现金需求的同时实现可持续增长，仍是其面临的关键挑战；不过，上个月完成的15亿美元融资有助于其延长流动性支持期。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL